. Amyloid-Beta Burden and Neuropsychological Test Performance in Cognitively Normal First-Degree Relatives at Varying Genetic Risk for Alzheimer's Disease. Human Amyloid Imaging Abstract. 2012 Jan 1;

Abstract:

In Alzheimer's disease (AD) there is strong evidence that brain amyloid deposition precedes the emergence of dementia by many years. This study investigated the relationship between APOE-e4 genotype, amyloid deposition, and neuropsychological test performance in pre-symptomatic individuals at varying genetic risk for AD.
Methods: Cognitively normal subjects aged0-66 with a first-degree family history for AD were genetically screened to select three groups: APOEgenotype e4e4 (n=15), e3e4 (n=15), and e3e3 (n=15), matched for age and sex. Subjects were then studied with C-11-Pittsburgh Compound B ([C-11]PiB) PET, MRI, and neuropsychological testing. PET and MR images were co-registered for application of a ROI template (AAL for SPM2) to generate regional time-activity curves with cerebellum as reference region. Parametric BPND images were then generated using SRTM2 such that BPND=0 reflected no specific binding. BPND was computed for a mean cortical ROI consisting of frontal, posterior cingulate-precuneus, lateral parietal, and lateral temporal ROIs.
Results: APOE-e4 carriers demonstrated significantly greater BPND (.16±.19) in comparison to non-carriers (.04±.09; F=7.00, p=.012, ANCOVA controlling for age and sex), with no dosage effect between e4e4 (.19±.13) and e3e4 (.14±.23) groups (Figure). Significant cortical [C-11]PiB uptake was observed in APOE-e4 carriers throughout the age range studied (as young as age1 in a e4e4 subject, Figure). There was no significant effect of APOEgenotype on neuropsychological test performance. There were also no significant associations between mean cortical [C-11]PiB BPND and neuropsychological test performance in the overall sample.
Conclusions: In cognitively normal individuals at high-risk for AD, significant amyloid deposition begins earlier than has been previously reported. Neuropsychological test results suggest minimal cognitive consequences of amyloid burden in these middle-aged “at risk” subjects. Detection of AD pathogenesis at a fully presymptomatic stage of disease may be necessary to enable the earliest therapeutic intervention for prevention trials.

Recommends

Please login to recommend the paper.

Comments

Comments on this Paper

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. Miami: Age and Amyloid—What Has ApoE Got to Do With It?